These pleiotropic effects may explain the failures in clinical trials of direct IL‐10 administration in inflammatory bowel disease [32], and there is therefore an argument for a targeted IL‐10 approach to control for any aberrant pro‐inflammatory effects. The gene discussed is IL10; the disease is inflammatory bowel disease.